RE:Merger Concessions"AEZS first quarter cash position was stated."
The more interesting question is what is the interest in licensing the diagnostic test. July 2023 AEZS said in a news release: "Further, based upon our active outreach and discussions, we expect to secure an alternate development and commercialization partner for Macrilen® for the U.S. and Canada.” Gilles would have known about the discussions and that would have shaped the desire for a merger. The pediatric clinical trial results expected in Q3 will be key, of course. The Strongbridge deal had ~C$40 million upfront cash adjusted for inflation. Even half of that would be a strong building block for the rest of the business plan.
As for cash if CZO is about to monitize that inventory and bring it down to normal levels that would be significant.
Q3 2023 US$38.8
Q4 2023 US$34
Q1 2024 US $29.5
That decline looks within reason and orderly.
CZO:
Q3 2023 Cash: C$11.4 ; inventories C$5.4
Q4 2023 Cash: C$8.84 ; inventories: C$5.3
Q1 2024 Cash: C$4.75 ; inventories: C$4.78